William G Haynes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7662096/publications.pdf

Version: 2024-02-01

		23567	24982
161	12,585	58	109
papers	citations	h-index	g-index
163	163	163	11069
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Obesity-Associated Hypertension. Hypertension, 2005, 45, 9-14.	2.7	688
2	Impairment of Endothelium-Dependent Vasodilation of Resistance Vessels in Patients With Obstructive Sleep Apnea. Circulation, 2000, 102, 2607-2610.	1.6	634
3	Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, The, 1994, 344, 852-854.	13.7	577
4	Role of Oxidant Stress in Endothelial Dysfunction Produced by Experimental Hyperhomocyst(e)inemia in Humans. Circulation, 1999, 100, 1161-1168.	1.6	398
5	Effects of obstructive sleep apnea on endothelin-1 and blood pressure. Journal of Hypertension, 1999, 17, 61-66.	0.5	394
6	Interactions Between the Melanocortin System and Leptin in Control of Sympathetic Nerve Traffic. Hypertension, 1999, 33, 542-547.	2.7	349
7	Endothelin as a regulator of cardiovascular function in health and disease. Journal of Hypertension, 1998, 16, 1081-1098.	0.5	320
8	Role of Selective Leptin Resistance in Diet-Induced Obesity Hypertension. Diabetes, 2005, 54, 2012-2018.	0.6	289
9	Sympathetic and Cardiorenal Actions of Leptin. Hypertension, 1997, 30, 619-623.	2.7	276
10	Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. Circulation, 1996, 93, 1860-1870.	1.6	257
11	Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. Journal of Hypertension, 1993, 11, 1375-1380.	0.5	243
12	Endothelin ET _A and ET _B Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation, 1995, 92, 357-363.	1.6	229
13	Impairments in microvascular reactivity are related to organ failure in human sepsis. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1065-H1071.	3.2	228
14	Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. Journal of Hypertension, 1999, 17, 1949-1953.	0.5	221
15	Xanthine Oxidase Inhibition Reverses Endothelial Dysfunction in Heavy Smokers. Circulation, 2003, 107, 416-421.	1.6	214
16	The Endothelin Family of Peptides: Local Hormones with Diverse Roles in Health and Disease?. Clinical Science, 1993, 84, 485-500.	4.3	213
17	Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model. Scientific Reports, 2017, 7, 14620.	3.3	205
18	The Concept of Selective Leptin Resistance: Evidence From Agouti Yellow Obese Mice. Diabetes, 2002, 51, 439-442.	0.6	202

#	Article	IF	CITATIONS
19	Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. Journal of Hypertension, 2002, 20, 1245-1250.	0.5	178
20	Obesity-Induced Hypertension. Hypertension, 1999, 33, 537-541.	2.7	171
21	Role of Melanocortin-4 Receptors in Mediating Renal Sympathoactivation to Leptin and Insulin. Journal of Neuroscience, 2003, 23, 5998-6004.	3.6	169
22	Hypothalamic ERK Mediates the Anorectic and Thermogenic Sympathetic Effects of Leptin. Diabetes, 2009, 58, 536-542.	0.6	169
23	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clinical Science, 2001, 100, 161-167.	4.3	166
24	Elevated Prevalence of Obesity, Metabolic Syndrome, and Cardiovascular Risk Factors in Bipolar Disorder. Annals of Clinical Psychiatry, 2008, 20, 131-137.	0.6	165
25	Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. Journal of Clinical Investigation, 2004, 114, 652-658.	8.2	162
26	Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertension Research, 2012, 35, 4-16.	2.7	159
27	Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo. Circulation, 1998, 97, 2323-2330.	1.6	158
28	Role of endothelin in cardiovascular disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 1-15.	1.7	158
29	Vasodilator Effects of Endothelin-Converting Enzyme Inhibition and Endothelin ET A Receptor Blockade in Chronic Heart Failure Patients Treated With ACE Inhibitors. Circulation, 1996, 94, 2131-2137.	1.6	148
30	Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity. Journal of Neuroscience, 2009, 29, 5916-5925.	3.6	144
31	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism, 2019, 22, 49-61.	6.5	140
32	Leptin Acts in the Central Nervous System to Produce Dose-Dependent Changes in Arterial Pressure. Hypertension, 2001, 37, 936-942.	2.7	138
33	Homocysteine: Role and implications in atherosclerosis. Current Atherosclerosis Reports, 2006, 8, 100-106.	4.8	129
34	Selective Resistance to Central Neural Administration of Leptin in Agouti Obese Mice. Hypertension, 2002, 39, 486-490.	2.7	114
35	A prospective study of the effect of haemorrhoidectomy on sphincter function and faecal continence. British Journal of Surgery, 2005, 69, 396-398.	0.3	113
36	Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney International, 1998, 53, 1068-1077.	5.2	110

3

#	Article	IF	CITATIONS
37	Interaction between leptin and sympathetic nervous system in hypertension. Current Hypertension Reports, 2000, 2, 311-318.	3.5	105
38	Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E891-E895.	3.5	103
39	Leptin and the Cardiovascular System. Endocrine Reviews, 2004, 59, 225-244.	6.7	98
40	Intracellular Mechanisms Involved in Leptin Regulation of Sympathetic Outflow. Hypertension, 2003, 41, 763-767.	2.7	97
41	Role of leptin in obesityâ€ r elated hypertension. Experimental Physiology, 2005, 90, 683-688.	2.0	97
42	Homocysteine: is it a clinically important cardiovascular risk factor?. Cleveland Clinic Journal of Medicine, 2004, 71, 729-734.	1.3	91
43	Effects of Leptin on Insulin Sensitivity in Normal Rats. Endocrinology, 1997, 138, 3395-3401.	2.8	77
44	Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovascular Drugs and Therapy, 2002, 16, 391-399.	2.6	74
45	Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney International, 1995, 48, 806-813.	5. 2	72
46	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clinical Science, 2001, 100, 161.	4.3	70
47	Periodontal Disease and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1309-1311.	2.4	68
48	Anoâ€rectal activity in man during rectal infusion of saline: a dynamic assessment of the anal continence mechanism Journal of Physiology, 1982, 330, 45-56.	2.9	66
49	Modeling human pancreatic beta cell dedifferentiation. Molecular Metabolism, 2018, 10, 74-86.	6.5	65
50	Effects of aging and atherosclerosis on endothelial and vascular smooth muscle function in humans. International Journal of Cardiology, 2006, 109, 201-206.	1.7	63
51	Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Current Psychiatry Reviews, 2012, 8, 25-36.	0.9	63
52	The increase in human plasma immunoreactive endothelin but not big endothelinâ€1 or its Câ€terminal fragment induced by systemic administration of the endothelin antagonist TAKâ€044. British Journal of Pharmacology, 1996, 119, 311-314.	5.4	62
53	Frequency response characteristics of sympathetically mediated vasomotor waves in humans. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1277-H1283.	3.2	62
54	Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism: Clinical and Experimental, 2004, 53, 1454-1461.	3.4	62

#	Article	IF	CITATIONS
55	Endothelin production in sepsis and the adult respiratory distress syndrome. Intensive Care Medicine, 1996, 22, 52-56.	8.2	61
56	Plasma leptin in diabetic and insulin-treated diabetic and normal rats. Metabolism: Clinical and Experimental, 1998, 47, 584-591.	3.4	61
57	Does Leptin Stimulate Nitric Oxide to Oppose the Effects of Sympathetic Activation?. Hypertension, 2001, 38, 1081-1086.	2.7	61
58	Endothelium-Dependent Modulation of Responses to Endothelin-1 in Human Veins. Clinical Science, 1993, 84, 427-433.	4.3	59
59	Role of Corticotrophin-Releasing Factor in Effects of Leptin on Sympathetic Nerve Activity and Arterial Pressure. Hypertension, 2001, 38, 384-388.	2.7	59
60	L-NMMA Increases blood pressure in man. Lancet, The, 1993, 342, 931-932.	13.7	58
61	A leptin-sympathetic-leptin feedback loop: potential implications for regulation of arterial pressure and body fat. Acta Physiologica Scandinavica, 2003, 177, 345-349.	2.2	55
62	Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction. Journal of Diabetes and Its Complications, 2007, 21, 149-157.	2.3	53
63	Vasculopathy Related to Manic/Hypomanic Symptom Burden and First-Generation Antipsychotics in a Sub-Sample from the Collaborative Depression Study. Psychotherapy and Psychosomatics, 2012, 81, 235-243.	8.8	53
64	Evidence for accelerated vascular aging in bipolar disorder. Journal of Psychosomatic Research, 2012, 73, 175-179.	2.6	51
65	Leptin Potentiates Thermogenic Sympathetic Responses to Hypothermia: A Receptor-Mediated Effect. Diabetes, 2002, 51, 2434-2440.	0.6	50
66	Cardiovascular and sympathetic effects of leptin. Current Hypertension Reports, 2002, 4, 119-125.	3.5	50
67	Endothelins as Regulators of Vascular Tone in Man. Clinical Science, 1995, 88, 509-517.	4.3	49
68	Phosphoramidon inhibition of the <i>in vivo</i> conversion of big endothelinâ€1 to endothelinâ€1 in the human forearm. British Journal of Pharmacology, 1995, 116, 1821-1828.	5.4	47
69	Resistance vessel endothelial function in healthy humans during transient postprandial hypertriglyceridemia. American Journal of Cardiology, 2000, 85, 381-385.	1.6	47
70	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 3228-3234.	0.7	47
71	Endothelial effects of leptin: Implications in health and diseases. Current Diabetes Reports, 2005, 5, 260-266.	4.2	46
72	Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, 1702-1709.	1.0	44

#	Article	IF	Citations
73	Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. American Journal of Cardiology, 2001, 88, 285-290.	1.6	43
74	Leptin signaling pathways in the central nervous system: interactions between neuropeptide Y and melanocortins. BioEssays, 2001, 23, 1095-1099.	2.5	42
75	A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2183-2185.	2.4	42
76	Leptin and Body Fat in Type 2 Diabetes and Monodrug Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1543-1553.	3.6	40
77	Differential modulation of leptin-induced sympathoexcitation by baroreflex activation. Journal of Hypertension, 2002, 20, 1633-1641.	0.5	39
78	Dissociation Between Sympathetic Nerve Traffic and Sympathetically Mediated Vascular Tone in Normotensive Human Obesity. Hypertension, 2008, 52, 687-695.	2.7	39
79	Nitric oxide in liver failure. Lancet, The, 1991, 338, 1590.	13.7	38
80	Endothelin receptor antagonism in patients with chronic heart failure. Cardiovascular Research, 2000, 47, 166-172.	3.8	38
81	Impaired skeletal muscle and skin microcirculatory function in human obesity. Journal of Hypertension, 2002, 20, 1401-1405.	0.5	38
82	Obesity-related hypertension: Is there a role for selective leptin resistance?. Current Hypertension Reports, 2004, 6, 230-235.	3.5	38
83	Acute myocardial infarctions, strokes and influenza: seasonal and pandemic effects. Epidemiology and Infection, 2013, 141, 735-744.	2.1	37
84	Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: Safety, walking distance and endothelial function. Vascular Medicine, 2014, 19, 9-17.	1.5	37
85	Effect of hyperhomocysteinemia on protein C activation and activity. Blood, 2002, 100, 2108-2112.	1.4	36
86	Antecedent Hypoglycemia, Catecholamine Depletion, and Subsequent Sympathetic Neural Responses. Endocrinology, 2006, 147, 2781-2788.	2.8	35
87	The effects of short-term passive smoke exposure on endothelium-dependent and independent vasodilation. Journal of Hypertension, 1999, 17, 1395-1401.	0.5	32
88	Blood Vessel Function and Cognition in Elderly Patients With Atherosclerosis. Stroke, 2004, 35, e369-72.	2.0	32
89	NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity, 2007, 15, 2027-2042.	3.0	32
90	What Is the Most Appropriate Methodology for Detection of Conduit Artery Endothelial Dysfunction?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1172-1176.	2.4	31

#	Article	lF	Citations
91	Loss of Leptin Actions in Obesity: Two Concepts with Cardiovascular Implications. Clinical and Experimental Hypertension, 2004, 26, 629-636.	1.3	30
92	Arterial compliance and endothelial function. Current Diabetes Reports, 2007, 7, 269-275.	4.2	30
93	Homocysteine as a novel risk factor for atherosclerosis. Current Opinion in Cardiology, 1999, 14, 283-291.	1.8	28
94	Reduced endogenous endothelin-1–mediated vascular tone in chronic renal failure. Kidney International, 1999, 55, 613-620.	5.2	27
95	Acute Neuropsychological Functioning Following Cardiosurgical Interventions Associated With the Production of Intraoperative Cerebral Microemboli. Clinical Neuropsychologist, 2002, 16, 463-471.	2.3	26
96	Neuropsychological Performance Is Associated With Vascular Function in Patients With Atherosclerotic Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 141-146.	2.4	26
97	Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. Clinical Nephrology, 2012, 78, 1-9.	0.7	25
98	Plasma endothelin following cardiac arrest: differences between survivors and non-survivors. Resuscitation, 1994, 27, 117-122.	3.0	22
99	Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. American Journal of Cardiology, 2004, 93, 664-668.	1.6	22
100	Association of Anxiety With Resistance Vessel Dysfunction in Human Atherosclerosis. Psychosomatic Medicine, 2013, 75, 537-544.	2.0	22
101	Does leptin cause functional peripheral sympatholysis?. American Journal of Hypertension, 2001, 14, 615-618.	2.0	21
102	Rate of Weight Gain and Cardiometabolic Abnormalities in Children andÂAdolescents. Journal of Pediatrics, 2012, 161, 1010-1015.e1.	1.8	21
103	Body Fat Indices and Biomarkers of Inflammation: A Cross-Sectional Study with Implications for Obesity and Peri-implant Oral Health. International Journal of Oral and Maxillofacial Implants, 2014, 29, 1429-1434.	1.4	21
104	Leptin and the central neural mechanisms of obesity hypertension. Drugs of Today, 2002, 38, 807.	2.4	21
105	Endothelins come of age. Lancet, The, 1993, 342, 1439-1440.	13.7	20
106	Vascular function is not impaired early in the course of bipolar disorder. Journal of Psychosomatic Research, 2012, 72, 195-198.	2.6	20
107	SUMO-specific protease 2 mediates leptin-induced fatty acid oxidation in skeletal muscle. Metabolism: Clinical and Experimental, 2019, 95, 27-35.	3.4	20
108	Triglyceride-Rich Lipoproteins and Vascular Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 153-155.	2.4	17

#	Article	IF	CITATIONS
109	Effects of antipsychotic drugs on cardiovascular variability in participants with bipolar disorder. Human Psychopharmacology, 2014, 29, 145-151.	1.5	17
110	Screening, Diagnosis, and Treatment of Dyslipidemia Among Persons With Persistent Mental Illness: A Literature Review. Psychiatric Services, 2012, 63, 693-701.	2.0	16
111	Genetic Characterization of the â€~New' Harlan Sprague Dawley Dahl Salt-Sensitive Rats. Hypertension, 1996, 27, 546-551.	2.7	16
112	Nitric oxide and gallâ€bladder motor function. Alimentary Pharmacology and Therapeutics, 1998, 12, 425-432.	3.7	15
113	Bosentan in Essential Hypertension. New England Journal of Medicine, 1998, 339, 346-347.	27.0	15
114	Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 2000, 98, 65-70.	4.3	15
115	Hemodynamic consequences of neuropeptide Y-induced obesity. American Journal of Hypertension, 2002, 15, 137-142.	2.0	15
116	α ₂ -Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H2606-H2611.	3.2	14
117	The potassium channel opener BRL 38227 inhibits binding of [1251]-labelled endothelin-1 to rat cardiac membranes. Biochemical and Biophysical Research Communications, 1992, 185, 630-635.	2.1	13
118	Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. Clinical Science, 2002, 103, 53S-58S.	4.3	13
119	Sildenafil Increases Sympathetically Mediated Vascular Tone in Humans. American Journal of Hypertension, 2013, 26, 762-769.	2.0	13
120	Endothelium-Dependent Modulation of Venoconstriction to Sarafotoxin S6c in Human Veins In Vivo. Journal of Cardiovascular Pharmacology, 1995, 26, S180-182.	1.9	13
121	Venoconstriction to Endothelin-1 in Humans Is Attenuated by Local Generation of Prostacyclin But Not Nitric Oxide. Journal of Cardiovascular Pharmacology, 1993, 22, S317-S320.	1.9	12
122	Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 2000, 98, 65.	4.3	12
123	Lack of dilator effect of leptin in the hindlimb vascular bed of conscious rats. European Journal of Pharmacology, 2005, 518, 175-181.	3. 5	12
124	Vascular smooth muscle function is associated with initiation and processing speed in patients with atherosclerotic vascular disease. Journal of the International Neuropsychological Society, 2008, 14, 535-541.	1.8	12
125	Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. Pharmacotherapy, 2011, 31, 806-812.	2.6	12
126	Measurement of C-Terminal Fragment of Big Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S34-36.	1.9	11

#	Article	IF	Citations
127	Finger volume pulse waveforms facilitate reliable assessment of heart rate variability, but not blood pressure variability or baroreflex function. BMC Cardiovascular Disorders, 2014, 14, 180.	1.7	11
128	Reduced venous responsiveness to endothelinâ€1 but not noradrenaline in hypertensive chronic renal failure. Nephrology Dialysis Transplantation, 2001, 16, 295-301.	0.7	10
129	Effect of hyperhomocysteinemia induced by methionine administration on flow-mediated dilatation of the brachial artery in healthy subjects. American Journal of Cardiology, 2005, 95, 428-430.	1.6	10
130	Predictors of Subjective Cognitive Difficulties in Older Adults With Atherosclerotic Vascular Disease. American Journal of Geriatric Psychiatry, 2007, 15, 328-334.	1.2	10
131	White matter fractional anisotropy is inversely related to anxious symptoms in older adults with atherosclerosis. International Journal of Geriatric Psychiatry, 2013, 28, 1069-1076.	2.7	10
132	Hemoglobin A1c and C-reactive protein are independently associated with blunted nocturnal blood pressure dipping in obesity-related prediabetes. Hypertension Research, 2018, 41, 33-38.	2.7	9
133	Endothelin-1 and Aggregation of Human Platelets In Vitro. Journal of Cardiovascular Pharmacology, 1993, 22, S204-S206.	1.9	7
134	Higher augmentation index is associated with tensionâ€ŧype headache and migraine in middleâ€aged/older humans with obesity. Obesity, 2016, 24, 865-870.	3.0	7
135	Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. Diabetologia, 2021, 64, 2773-2778.	6.3	7
136	The Role of Endothelin-1 in Cardiovascular Physiology and Pathophysiology. Scottish Medical Journal, 1995, 40, 69-71.	1.3	6
137	Sibutramine and the sympathetic nervous system in obese humans. Clinical Autonomic Research, 2005, 15, 189-192.	2.5	6
138	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opinion on Emerging Drugs, 2005, 10, 643-660.	2.4	5
139	Unilateral vs. bilateral ultrasound in the monitoring of cerebral microemboli. Ultrasound in Medicine and Biology, 2001, 27, 757-760.	1.5	4
140	Dietary and Medical Therapy of Obesity. Surgical Clinics of North America, 2005, 85, 703-723.	1.5	4
141	Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. British Journal of Clinical Pharmacology, 1993, 36, 293-301.	2.4	3
142	Pharmacotherapy of obesity: lessons from clinical trials in hypertension. Journal of Hypertension, 2002, 20, 1731-1735.	0.5	3
143	Leptin administration to normal rats does not alter catecholamine responsiveness to insulin-induced hypoglycemia. Metabolism: Clinical and Experimental, 2003, 52, 1484-1490.	3.4	3
144	LDL Cholesteryl Oleate. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1228-1230.	2.4	3

#	Article	IF	Citations
145	Physiologic Role of Endothelin in Maintenance of Vascular Tone in Humans. Journal of Cardiovascular Pharmacology, 1995, 26, S183-185.	1.9	3
146	Cholesterol, mood, and vascular health: Untangling the relationship: Does low cholesterol predispose to depression and suicide, or vice versa?. Current Psychiatry, 2010, 9, 17-A.	1.7	3
147	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1064-1064.	2.4	2
148	Gender differences in neuropsychological performance in individuals with atherosclerosis: Impact of vascular function. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 9-16.	1.3	2
149	Membranous Nephropathy With Renal Salt Wasting: Role of Neurohumoral Factors in Sodium Retention. American Journal of Kidney Diseases, 2012, 60, 444-448.	1.9	2
150	Flosequinan in heart failure. Lancet, The, 1993, 341, 1100-1101.	13.7	1
151	Does nitric oxide synthesis really contribute to systemic blood pressure control?. Journal of Hypertension, 1995, 13, 709.	0.5	1
152	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. Clinical Pharmacology and Therapeutics, 2000, 68, 67-74.	4.7	1
153	Obesity does not increase sympathetic vascular tone in hypertensives. American Journal of Hypertension, 2005, 18, A195-A196.	2.0	1
154	Forearm Vasoconstriction to Endothelin-1 Is Mediated by ETA and ETB Receptors In Vivo in Humans. Journal of Cardiovascular Pharmacology, 1995, 26, S40-43.	1.9	1
155	Leptin Signaling in the Central Nervous System. , 2004, , 86-VI.		1
156	Increase in skin microcirculatory blood flow after local renin inhibition in man. Journal of Hypertension, 1991, 9, S230.	0.5	1
157	Measurement of C-Terminal Fragment of Big Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S34-36.	1.9	1
158	The Endothelins. Principles of Medical Biology, 1997, 10, 543-572.	0.1	0
159	Does Cuff Location for FMD Matter in Smokers?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, .	2.4	0
160	Role of PI3 kinase in mediating renal sympathoactivation to leptin in obesity. FASEB Journal, 2007, 21, A1193.	0.5	0
161	The selectivity of leptin resistance depends on the severity of dietâ€induced obesity in normotensive and borderline hypertensive mice. FASEB Journal, 2007, 21, A459.	0.5	O